Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).

@article{Florent1996PlacebocontrolledCT,
  title={Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Th{\'e}rapeutiques des Affections Inflammatoires Digestives (GETAID).},
  author={CH. Florent and Antoine Cortot and P. Quandale and T Sahmound and Robert Modigliani and Elizabeth Sarfaty and Patrice D Valleur and Jean Louis Dupas and M O Daurat and Jean Luc Faucheron and Eric Lerebours and Françis Michot and Jacques Belaiche and Nicolas L. Jacquet and Jean Claude Soul{\'e} and Nathaniel Rothman and Jean Pierre Gendre and Michel Malafosse},
  journal={European journal of gastroenterology & hepatology},
  year={1996},
  volume={8 3},
  pages={
          229-33
        }
}
OBJECTIVE Endoscopic postoperative recurrences occur early after 'curative' surgery for Crohn's disease. Pentasa has been shown to be effective in the maintenance treatment of quiescent Crohn's disease. The aim of this study was to test the efficacy of a 12-week oral intake of Claversal in the prevention of endoscopic recurrences after 'curative' resection for ileal, colonic or ileocolonic Crohn's disease. We conducted a multicentre double-blind controlled trial comparing Claversal (1g tid… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 35 CITATIONS

Similar Papers

Loading similar papers…